Standard Lithium Ltd. : Standard Lithium Commences CSAMT/MT Geophysical Survey at Bristol Lake, Mojave Project, California
VANCOUVER, British Columbia, June 29, 2017 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLL) (FRA:S5L) (OTCQX:STLHF) is pleased to announce that it has commenced a detailed and large-scale Controlled-Source Audio-Magnetotellurics / Magnetotellurics (CSAMT/MT) geophysical survey at the Company's Bristol Lake Project, in the Mojave area of California. The survey is being conducted in order to help better define the extent of highly conductive brine resources in the deep infilled basin that underlies SLL's Project area (brine-bearing basin is up to 1.2 km thick beneath the Project area, as revealed by recent gravity survey work; see news release dated 5th June). The survey is being completed on Standard's extensive 16,000+ acre landholding in the Bristol Lake basin, and will also be extended onto adjacent brine-producing properties in the basin, thanks to the kind cooperation of our neighbours.
Standard Lithium has retained Hasbrouck Geophysics to perform data acquisition and interpretation. Hasbrouck are ideally suited to performing the work as they have extensive experience conducting geophysical surveys in many brine-bearing basins across the southwestern US. Hasbrouck and their team have mobilised to site and expect that data acquisition should take approximately 2 weeks to complete given the detailed nature of the survey and the large size of the resource area, and that initial interpretation should be available for Standard's technical team to assess in the second half of July. Results from the CSAMT/MT survey will also be used to help scope and determine locations for the next phases of Standard's resource assessment program for the Bristol Lake Project.
Dr. Andy Robinson, COO and President of Standard Lithium, commented: "We're delighted to be partnering with Hasbrouck Geophysics as they bring their breadth of exploration geophysical knowledge to bear on our Bristol Lake Project. Our team has completed several previous surveys with Hasbrouck and we look forward to seeing their interpretation of the lateral and vertical extent of the brine deposits that are present beneath our Project area. Results from this phase of work will be very helpful in determining final locations for a proposed drilling programme that will take place in the second half of 2017."
Raymond Spanjers, Certified Professional Geologist (SME No. 3041730), is a qualified person as defined by NI 43-101, and has supervised the preparation of the scientific and technical information that forms the basis for this news release. Mr. Spanjers is not independent of the Company as he is an officer in his role as Vice President, Exploration and Development.
About Standard Lithium
Standard's value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovation & results oriented management team with a strong focus on technical skills. The Company is currently focused on the immediate exploration and development of its 16,000+ acre Bristol Lake, Brine Project located in the Mojave region of San Bernardino County, California. The location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. Standard also recently announced the acquisition of the 41,000+ acre Paradox Basin Project located in Grand County, Utah.
For further information, contact Anthony Alvaro at 604.763.5388.
On behalf of the Board,
Standard Lithium Ltd.
Robert Mintak, CEO & Director
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain certain "Forward-Looking Statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words "anticipate", "believe", "estimate", "expect", "target, "plan", "forecast", "may", "schedule" and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Standard Lithium Ltd. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Leading Medical Organizations Update Guideline for Molecular Testing and Targeted Therapies in Lung Cancer23.1.2018 21:11 | Pressmeddelande
DENVER, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide. To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies-the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)-have updated their 2013 evidence-based guideline. Published today in early online release, the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors," continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment. Targeted cancer therapies are drugs or other treatments that block the spread of cancer by interfering with specific molec
CashBet Seeks $40 Million for World's Only Complete Crypto-Ready Mobile iGaming Platform23.1.2018 16:31 | Pressmeddelande
Gaming and cryptocurrency industry leaders develop blockchain-based iGaming platform improving trust, speed, access, costs, and content availability OAKLAND, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Leading mobile-first iGaming platform provider CashBet (https://coin.cashbet.com/) today announced it seeks to raise $40 million through an Initial Coin Offering (ICO) to develop the world's first complete crypto-ready mobile iGaming platform. Interactive gaming, which includes real money, social, skill-based, esports and sports betting, hit $91 billion in 2016, led by mobile gaming. Despite strong growth, current iGaming operations continue to face three major issues: trust, speed, and cost. CashBet is the first and only vertically integrated iGaming solution to leverage blockchain technology for transparent operations, increased speed, and lower transaction fees. The CashBet Coin will be available in pre-sale starting January 24, 2018 at 5:00 p.m. GMT, with a 20 percent discount offered.
BrandSafway Announces Acquisition of Venko Groep BV23.1.2018 16:30 | Pressmeddelande
Combined customers to benefit from broader range of services and greater depth of expertise KENNESAW, GA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has acquired Venko Groep BV, a portfolio company of Mentha Capital, effective January 1, 2018. Moving forward, the company will operate as Venko, A BrandSafway Company and become a part of Brand Energy & Infrastructure Services (Brand) in Europe. "We're excited to announce the closing of the acquisition of Venko," said Dave Witsken, President of Energy and Industrial for BrandSafway. "Venko is a leading offshore coatings maintenance provider for platforms in Europe. By leveraging the highly specialized knowledge and capabilities of Venko, we will be able to provide expanded coatings services to Brand's European customers. At the same time, with our support, Venko will now be able to offer their customers a broader inventory of access equipment and additional industrial services, such as insulation an
Data on Novel Humanized Models for Targeted Immunotherapy Development, a CrownBio Conference Talk on January 24th, 201823.1.2018 14:53 | Pressmeddelande
SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will unveil data supporting use of its cost-effective, humanized drug target models at the Tumor Models Conference in San Francisco tomorrow, Wednesday, January 24th, 2018. Humanized research tools are crucial to the development of target-specific immunotherapies like pembrolizumab and ipilimumab. To help improve research in this burgeoning field, CrownBio has developed a humanized platform that informs the preclinical pharmacology of targeted immunotherapies, including solutions for PD-1, PD-L1, OX40, and CD3E. Constituent models feature fully functional murine immunity with humanized drug targets that can be used in conjunction with syngeneic tumor cell lines engineered to expr
Music Legend Joey Fatone Will Be Celebrity Grand Marshal Of First Ever 15th Annual World's Shortest St. Patrick's Day Parade In Hot Springs, Arkansas23.1.2018 13:56 | Pressmeddelande
HOT SPRINGS NATIONAL PARK, Ark., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Music legend Joey Fatone, who soared to worldwide fame as a member of boy-band *NSYNC, will be celebrity grand marshal of the First Ever 15th Annual World's Shortest St. Patrick's Day Parade in downtown Hot Springs March 17, 2018, reports Hot Springs Convention & Visitors Bureau. He'll round out a quartet of celebrities who will be part of the quirky parade, which annually draws throngs to world-famous Bridge Street, the shortest street in the world in everyday use - 98 feet long. Jon Heder, who became famous as Napoleon Dynamite, will be the parade's official starter. The 2018 parade will begin at 7:30 p.m., an hour later than previous years. The start time was changed to allow Oaklawn racing fans plenty of time to enjoy the live racing including The Rebel Stakes at Oaklawn Park, and still get downtown for the start of the parade. Morris Day and the Time will perform a free concert at the conclusion of the parade. On F
HemCheck och Region Västmanland i studie om hemolyserade blodgasprov23.1.2018 13:30 | Pressmeddelande
PRESSMEDDELANDE HemCheck och Region Västmanland i studie om hemolyserade blodgasprov Karlstad 23 januari 2018: HemCheck Sweden AB meddelar idag att bolaget tecknat ett avtal med Region Västmanland avseende en studie för att kartlägga förekomsten av hemolys i blodgasprover tagna vid akutmottagningen på Västmanlands Sjukhus i Västerås. Blodgasanalys är ett blodprov som tas rutinmässigt på sjukhus och som är ett centralt verktyg när snabba svar krävs för kritiska diagnoser. Blodgasanalysen påverkas, liksom vanlig blodprovstagning, av hemolys, men i vilken omfattning är ännu inte lika väl dokumenterat. -Idag utförs ingen hemolyskontroll på blodgasprov. Avsikten med studien är att undersöka förekomsten av hemolys i blod som analyserats i blodgasapparater och se om det kan detekteras med hjälp av ett enkelt test. Det är glädjande att vi som ett första steg i det arbetet kan genomföra en så viktig studie ihop med Region Västmanland och Västmanlands Sjukhus Västerås. Vi ser att väl fungerande
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum